Navigation Links
Vion Reports 2008 Third Quarter and Nine-Month Results
Date:11/3/2008

n.

Alan Kessman, Chief Executive Officer, commented, "We continue to focus on the preparation of the New Drug Application (NDA) for our lead anticancer agent laromustine (Cloretazine, VNP40101M). The NDA filing will be based on our two Phase II trials in elderly patients with acute myelogenous leukemia. Our plan is to file this NDA in early 2009."

Third Quarter Conference Call

The Company announced that it would hold a conference call on Thursday, November 6, 2008 to discuss its 2008 third quarter financial results. The call will begin at 8:30 a.m. Eastern Time.

To participate in the conference call, please dial (800) 831-6270 in the U.S. ((617) 213-8858 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 85439318.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 37383579. The replay will be available through Thursday, November 20, 2008.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R), VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de no
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008
2. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
3. NxStage Reports Third Quarter 2008 Financial Results
4. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
5. The Ensign Group, Inc. Reports Third Quarter 2008 Earnings; Reaffirms 2008 Guidance
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
8. Nuvelo Reports Third Quarter 2008 Financial Results
9. Claimsnet.com Reports Third Quarter 2008 Results
10. Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need
11. Palomar Medical Reports Financial Results for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Wittenberg, MD, uses an,investor,s technology to yield the ... 6 When Scottsdale businessman,Warren Kaplan decided a ... had no,idea that an innovative medical product Possis ... gifted interventional radiologist - save his daughter,s life., ...
... Nov. 6 Repligen Corporation,(Nasdaq: RGEN ) ... Phase 2b,clinical trial to evaluate the use of ... bipolar depression. This Phase 2b study is a,multi-center, ... patients with bipolar depression will receive,either RG2417 or ...
... SALT LAKE CITY, Nov. 6 "In a remarkable ... history of cosmetics, women around the,country have been applying ... of fine lines, wrinkles and crows, feet." Five years ... a revolution in the cosmetic,industry: a little-known American stretch-mark ...
... 6 Performance Health Technologies,Inc. (PHT), a leader ... guide and monitor exercise and rehabilitation, announced,today that ... the September 5 edition of "60 Second Science," ... "Virtual Rehabilitation: Wireless Motion Sensor to Help,Treat That ...
... NEW YORK, Nov. 6 According to the ... The African,American community is one of the groups ... diagnosed. With November being National Diabetes Month,Black Expressions(R) ... that raise,awareness about diabetes and offer information about ...
... Salud to Use Pan-Enterprise Search Platform to,Identify ... and SAN FRANCISCO, November 6 /PRNewswire-FirstCall/,-- Autonomy ... global leader in,infrastructure software for the enterprise ... Spain,s most innovative health service,provider, has selected ...
Cached Medicine News:Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 2Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 2Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 3Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 2Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 3Health News:National Diabetes Month Book Suggestions From Black Expressions(R) Book Club 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 3Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 4
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... April 21 Strativa,Pharmaceuticals, the proprietary products ... PRX ) today announced that its development ... a Phase III,study of Loramyc(R) (miconazole Lauriad(R)) ... candidiasis (OPC)., Top line data show ...
... Nostrum, a privately-held,company based in Edison, ... completed its early, primate, proof-of-concept study for ... SMRX11. Nostrum,s,Symmetrix subsidiary, based in Singapore, is ... from the Institute of Microbial,Technology, Chandigarh, India, ...
Cached Medicine Technology:Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 2Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 3Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 2
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... of diabetes in order to maintain tight control ... way to reduce or even prevent diabetes-related complications. ... a diabetes patients quality of life, however, is ... been the guiding factors in the development of ...
... the CGMS System Gold can assist you ... based on detailed glycemic profiles. Its also ... motivation and collaboration with patients.1, ,While ... all diabetes patients, it may be of ...
... The GlucoWatch G2 Biographer is intended for ... levels in adults (aged 18 and older) ... diabetes. Parents should supervise the use of ... G2 Biographer is intended to supplement, not ...
Medicine Products: